ArticleCancers2023
Comparison of Recurrence Patterns between Adenocarcinoma and Squamous Cell Carcinoma after Stereotactic Body Radiotherapy for Early-Stage Lung Cancer.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics in distinguishing between lung adenocarcinoma and lung squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Image-guided radiofrequency ablation for treatment of stage I non-small cell lung cancer in 111 high-risk patients: Analysis of prognostic variables.The Journal of thoracic and cardiovascular surgery · 2026Article
- Unique Clinical Features of Imaging-Stage I Peripheral Lung Squamous Cell Carcinoma: A Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Development and validation of a machine learning model to predict early recurrence after surgery in NSCLC patients.Scientific reports · 2025Article
- Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy.Journal of cancer research and clinical oncology · 2025Article
- Effects of target coverage on local recurrence in stereotactic body radiotherapy for early-stage lung squamous cell carcinoma.Japanese journal of radiology · 2025Article
- Re-irradiation for local recurrence after definitive stereotactic body radiotherapy for early-stage non-small cell lung cancer.Translational lung cancer research · 2025Article
- Stereotactic body radiotherapy for central non-small cell lung cancer: risk analysis of radiation pneumonitis and bronchial dose constraints.Journal of radiation research · 2025Article
- Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity.Scientific reports · 2024Article
- Article
- Symptomatic radiation-induced rib fractures after stereotactic body radiotherapy for early-stage non-small cell lung cancer.Clinical and translational radiation oncology · 2023Article
- Clinical and dosimetric factors for symptomatic radiation pneumonitis after stereotactic body radiotherapy for early-stage non-small cell lung cancer.Clinical and translational radiation oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We compared recurrence patterns between adenocarcinoma (ADC) and squamous cell carcinoma (SCC) after stereotactic body radiotherapy (SBRT) for early-stage lung cancer. Patients with ADC and SCC histology, who were treated with SBRT for clinical stage IA1-IIA lung cancer at our institution, were included in the analysis. The rates of disease-free survival (DFS), overall survival (OS), local recurrence (LR), lymph node metastasis (LNM), and distant metastasis (DM) were calculated using the Kaplan-Meier method or the cumulative incidence function. Among the 204 patients analyzed, 138 and 66 were in the ADC and SCC groups, respectively. The median follow-up period was 60 months. The five-year DFS and OS rates were 57% vs. 41% and 69% vs. 48% in the ADC and SCC groups, respectively (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.